CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

SARS-CoV-2Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug2373 Study of immune-mediated mechanisms in patients tested positive for SARS-CoV-2 Wiki 0.71
drug1163 Ibrutinib Wiki 0.50
drug1822 Placebo Wiki 0.04

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D055370 Lung Injury NIH 0.15
D045169 Severe Acute Respiratory Syndrome NIH 0.07
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials

1 Usability Study of Home Collection and Mailing With SARS-CoV-2 Test Specimen Collection Materials (2020-06)

The primary objective is to determine the usability of the SARS-CoV-2 Specimen Collection Materials for at-home collection and mailing of sample to the testing laboratory.

NCT04395391 COVID-19 Diagnostic Test: SARS-CoV-2

Primary Outcomes

Description: The percent of samples from the fully enrolled cohort to return a valid SARS-CoV-2 test result (positive, not detected, or inconclusive)

Measure: Valid SARS-CoV-2 Test

Time: Subjects are assessed at enrollment

2 Repeated Employee Testing for Understanding Our Recovery to Normal

The purpose of this research study is 1) to conduct a prospective longitudinal surveillance research trial, enrolling up to 200 CCHMC employees as they come back to work, and then following their clinical and laboratory parameters for up to 12 months; and 2) to support the ongoing development of diagnostic techniques for COVID-19. The overall goal is to investigate patterns of SARS-COV-2 infection, including immunological recovery and genetic risk factors, among CCHMC employees to better understand how to safely reintroduce the CCHMC work force back into their normal routines.

NCT04472793 COVID-19 Diagnostic Test: SARS-CoV-2

Primary Outcomes

Description: Acquired COVID is defined as testing negative for COVID at baseline and having 1 or more weekly nasal swab samples testing positive for the virus by PCR

Measure: The 6-month cumulative incidence of acquired COVID infection in the study cohort.

Time: Weekly for 6 months

No related HPO nodes (Using clinical trials)